21 CFR 211.204: Returned drug products
Requires manufacturers to identify and hold returned drug products, destroy those with doubtful safety or quality unless testing proves them acceptable, keep detailed return records, investigate implicated batches, and follow written procedures for handling returns.
Part 211, Current Good Manufacturing Practice for Finished Pharmaceuticals · Subpart K, Returned and Salvaged Drug Products
Recent 483s citing 211.204
- GOJO Industries LLC · —Drug products are not stored under appropriate conditions of temperature, humidity… Apr 9, 2026
- Nosch Labs Pvt. Ltd. · Hyderabad, Telangana, IndiaProcedures are not followed for return products… Sep 13, 2024
- Avion Pharmaceuticals, LLC · Alpharetta, GeorgiaProcedures describing the holding, testing and reprocessing of returned drug… Nov 8, 2023
- APOTHECON PHARMACEUTICALS PRIVATE LIMITED · Vadodara, Gujarat, IndiaReturned drug products are not identified as such and held… Jan 27, 2023
- Tokyo Chemical Industry Co., Ltd. · Fukaya, Saitama, JapanOct 19, 2018
The regulation text
§ 211.204 Returned drug products.
Returned drug products shall be identified as such and held. If the conditions under which returned drug products have been held, stored, or shipped before or during their return, or if the condition of the drug product, its container, carton, or labeling, as a result of storage or shipping, casts doubt on the safety, identity, strength, quality or purity of the drug product, the returned drug product shall be destroyed unless examination, testing, or other investigations prove the drug product meets appropriate standards of safety, identity, strength, quality, or purity. A drug product may be reprocessed provided the subsequent drug product meets appropriate standards, specifications, and characteristics. Records of returned drug products shall be maintained and shall include the name and label potency of the drug product dosage form, lot number (or control number or batch number), reason for the return, quantity returned, date of disposition, and ultimate disposition of the returned drug product. If the reason for a drug product being returned implicates associated batches, an appropriate investigation shall be conducted in accordance with the requirements of § 211.192. Procedures for the holding, testing, and reprocessing of returned drug products shall be in writing and shall be followed.
Questions
What does 21 CFR 211.204 require?
Requires manufacturers to identify and hold returned drug products, destroy those with doubtful safety or quality unless testing proves them acceptable, keep detailed return records, investigate implicated batches, and follow written procedures for handling returns.
Which sections are cited alongside 211.204?
In the same 483s, investigators most often also cite 211.198 (Complaint files), 211.160 (General requirements), 211.68 (Automatic, mechanical, and electronic equipment), 211.192 (Production record review).